NasdaqGM:ZLABBiotechs
Zai Lab (NasdaqGM:ZLAB): Valuation Check After First Dosing in Global Phase 1/1b Trial for ZL-1503
Zai Lab (ZLAB) just dosed the first participant in its global Phase 1/1b trial for ZL-1503, an internally discovered bispecific antibody for atopic dermatitis, highlighting the company’s innovation pipeline and medium term upside potential.
See our latest analysis for Zai Lab.
That milestone comes after a choppy stretch for investors, with the 90 day share price return down 45.58 percent and the 1 year total shareholder return at negative 32.48 percent, suggesting sentiment may be cautious...